94 related articles for article (PubMed ID: 20186950)
21. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
22. Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity.
Kienlen-Campard P; Feyt C; Huysseune S; de Diesbach P; N'Kuli F; Courtoy PJ; Octave JN
J Neurosci Res; 2006 Nov; 84(6):1311-22. PubMed ID: 16941495
[TBL] [Abstract][Full Text] [Related]
23. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
[TBL] [Abstract][Full Text] [Related]
24. [The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].
Masuda S
Rinsho Ketsueki; 2006 Jul; 47(7):557-63. PubMed ID: 16910563
[No Abstract] [Full Text] [Related]
25. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
[TBL] [Abstract][Full Text] [Related]
26. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.
Siemers E; Skinner M; Dean RA; Gonzales C; Satterwhite J; Farlow M; Ness D; May PC
Clin Neuropharmacol; 2005; 28(3):126-32. PubMed ID: 15965311
[TBL] [Abstract][Full Text] [Related]
28. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
[TBL] [Abstract][Full Text] [Related]
29. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease.
Asberom T; Zhao Z; Bara TA; Clader JW; Greenlee WJ; Hyde LA; Josien HB; Li W; McPhail AT; Nomeir AA; Parker EM; Rajagopalan M; Song L; Wong GT; Zhang L; Zhang Q; Pissarnitski DA
Bioorg Med Chem Lett; 2007 Jan; 17(2):511-6. PubMed ID: 17079141
[TBL] [Abstract][Full Text] [Related]
30. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
31. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
32. BACE1 gene expression and protein degradation.
Zhou W; Qing H; Tong Y; Song W
Ann N Y Acad Sci; 2004 Dec; 1035():49-67. PubMed ID: 15681800
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
34. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Trechot P; Schmutz JL
Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
[No Abstract] [Full Text] [Related]
35. Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors.
Pu J; Kreft AF; Aschmies SH; Atchison KP; Berkowitz J; Caggiano TJ; Chlenov M; Diamantidis G; Harrison BL; Hu Y; Huryn D; Steven Jacobsen J; Jin M; Lipinski K; Lu P; Martone RL; Morris K; Sonnenberg-Reines J; Riddell DR; Sabalski J; Sun SC; Wagner E; Wang Y; Xu Z; Zhou H; Resnick L
Bioorg Med Chem; 2009 Jul; 17(13):4708-17. PubMed ID: 19443228
[TBL] [Abstract][Full Text] [Related]
36. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
[TBL] [Abstract][Full Text] [Related]
37. APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages.
Lefranc-Jullien S; Sunyach C; Checler F
J Neurochem; 2006 May; 97(3):807-17. PubMed ID: 16524370
[TBL] [Abstract][Full Text] [Related]
38. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells.
Peng Y; Jiang L; Lee DY; Schachter SC; Ma Z; Lemere CA
J Neurosci Res; 2006 Sep; 84(4):903-11. PubMed ID: 16862548
[TBL] [Abstract][Full Text] [Related]
39. A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets.
Liu WW; Todd S; Coulson DT; Irvine GB; Passmore AP; McGuinness B; McConville M; Craig D; Johnston JA
J Neurochem; 2009 Jan; 108(2):341-9. PubMed ID: 19094065
[TBL] [Abstract][Full Text] [Related]
40. Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression.
Quiroz-Baez R; Rojas E; Arias C
Neurochem Int; 2009 Dec; 55(7):662-70. PubMed ID: 19560504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
